Just as with secondary prevention in any ischemic stroke, I think looking at vascular risk factor control is really important. So regardless of the underlying etiology of their breakthrough stroke, you know, addressing things like blood pressure control, lipids, diabetes management, smoking cessation, these are all the kind of low-hanging fruit, let’s call it. And then next, I think, you know, we really have a lot to learn still about the management of breakthrough strokes in AF...
Just as with secondary prevention in any ischemic stroke, I think looking at vascular risk factor control is really important. So regardless of the underlying etiology of their breakthrough stroke, you know, addressing things like blood pressure control, lipids, diabetes management, smoking cessation, these are all the kind of low-hanging fruit, let’s call it. And then next, I think, you know, we really have a lot to learn still about the management of breakthrough strokes in AF. And so what I try to do is actually enroll these patients in clinical trials if it’s possible. So in these patients who do meet AF-BREACH criteria, I try to refer them to the LAAOS-4 trial is currently going on at my institution, which randomizes patients to left atrial appendage occlusion plus DOAC versus DOAC alone. And so I think it’s really important to use this as an opportunity to try to help answer the question for future patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.